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Purpose: To examine the effects of Ginkgo biloba extract EGb 761® on neuropsychiatric 
symptoms of dementia.
Patients and methods: Randomized, controlled, double-blind, multicenter clinical trial 
involving 410 outpatients with mild to moderate dementia (Alzheimer’s disease with or without 
cerebrovascular disease, vascular dementia), scoring at least 5 on the Neuropsychiatric Inventory 
(NPI), with at least one item score of 3 or more. Total scores on the SKT cognitive test battery 
(Erzigkeit’s short syndrome test) were between 9 and 23. After random allocation, the patients 
took 240 mg of EGb 761® or placebo once daily for a period of 24 weeks. Changes from baseline 
to week 24 in the NPI composite and in the SKT total score were the primary outcomes. The NPI 
distress score was chosen as a secondary outcome measure to evaluate caregivers’ distress.
Results: The NPI composite score improved by −3.2 (95% confidence interval −4.0 to −2.3) in 
patients taking EGb 761® (n = 202), but did not change (−0.9; 0.9) in those receiving placebo 
(n = 202), which resulted in a statistically significant difference in favor of EGb 761® (P , 0.001). 
Treatment with EGb 761® was significantly superior to placebo for the symptoms apathy/indif-
ference, sleep/night-time behavior, irritability/lability, depression/dysphoria, and aberrant motor 
behavior. Caregivers’ distress evaluation revealed similar baseline pattern and improvements.
Conclusion: Treatment with EGb 761®, at a once-daily dose of 240 mg, was safe, effectively 
alleviated behavioral and neuropsychiatric symptoms in patients with mild to moderate dementia, 
and improved the wellbeing of their caregivers.
Keywords: Alzheimer’s disease, vascular dementia, patients, caregivers, Ginkgo biloba, 
EGb 761®
Introduction
The primary risk factor for both Alzheimer’s disease (AD) and vascular dementia 
(VaD) is age. The extension of life expectancy results in a rising number of patients 
with dementia and associated symptoms. The core syndrome of dementia, which serves 
as a key diagnostic feature, is cognitive impairment, but neuropsychiatric symptoms 
(NPSs) are common as well. Almost all people with dementia are affected by these 
symptoms at some point during the progression of the disorder.1 This may result in 
long-term hospitalization, increased use of medication, and a decrease in quality of 
life for patients and caregivers.2
Prevalence of any one NPS was 61% in a cross-sectional study, and 69%, who were 
symptom-free at baseline, had at least one symptom when followed up 18 months later.3,4 
In another study, 75% of dementia patients exhibited at least one such symptom in the 
previous month; two or more symptoms were observed in 55% of cases.5 Between 43% Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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and 47% of patients with mild cognitive impairment (MCI) 
exhibited at least one neuropsychiatric symptom, and up 
to 80% of the demented patients had presented at least one 
neuropsychiatric symptom since the beginning of their cogni-
tive impairment.5,6 Neuropsychiatric symptoms are associ-
ated with dementia from its early beginning and cannot be 
described as concomitant features of advanced disease states.5 
Like cognitive disturbances, they should be considered as an 
integral part of the core psychopathology.5,7
There were no differences in the prevalence of NPSs in 
patients with AD type or other forms of dementia, including 
VaD, apart from the item aberrant motor behavior, which was 
more frequent in AD. The most frequent symptoms in demen-
tia patients were apathy, depression, and agitation/aggression.5 
NPS severity was no different between AD and VaD patients 
on initial assessment of a memory disorders clinic population 
with mild to moderate dementia. However, NPSs increased 
with severity of dementia in this group.8
Ginkgo biloba extract EGb 761® has been reported to 
be effective in the symptomatic treatment of dementia, in 
particular when NPSs are present.9–12 Clinically significant 
effects of EGb 761® on NPSs have been described for patients 
suffering from age-associated cognitive decline as well as for 
patients with dementia.13–15 The molecular basis of such effects 
is not yet fully understood, but there is evidence of neuro-
protective properties, including inhibition of synaptotoxic 
Aβ oligomer formation as well as antagonism of β-amyloid 
toxicity.16–19 EGb 761® is a polyvalent radical scavenger 
that improves mitochondrial function,20–22 decreases blood 
viscosity, and enhances microperfusion.23 Modulation of the 
serotonin system,24 increasing dopamine levels in prefrontal 
cortical areas,25 perhaps by inhibition of the norepinephrine 
transporter,26 attenuation of a hyperactivated hypothalamus–
pituitary–adrenal (HPA) axis,27–29 and improvement of 
neuronal insulin sensitivity may play a role, since these phar-
macodynamic actions of EGb 761® target pathomechanisms 
that are common to dementia and behavioral disorders.
Here we report on secondary analyses of data from a 
recently published clinical trial of a once-daily formulation con-
taining 240 mg of Ginkgo biloba extract EGb 761®.12 The goal 
of these secondary analyses was the assessment of treatment 
effects of EGb 761® on single NPSs in patients with dementia 
as well as on relieving the related caregiver distress.
Material and methods
The clinical trial was conducted in accordance with the 
Declaration of Helsinki, the International Conference on 
  Harmonization (ICH) guideline for good clinical practice 
(GCP), and the provisions of local laws.30 The protocol was 
approved by the Ethics Committee of the State Pharmacology 
Center at the Ukraine Ministry of Health. Before enrolment, 
oral and written informed consent was obtained from all 
patients and their caregivers. At a start-up meeting, investi-
gators and clinical staff involved in the trial were trained in 
GCP standards and legal requirements. Moreover, they were 
trained by experienced psychiatrists and neuropsychologists 
in the administration of tests and rating scales used for diag-
nosis and efficacy assessment.
study population
Patient selection, patient disposition, trial design, and   methods 
are described in detail elsewhere.12 Briefly, outpatients 
($50 years of age, 20 centers) with mild to moderate dementia 
due to probable AD (according to NINCDS/ADRDA research 
diagnostic criteria),31 possible AD (NINCDS/ADRDA) with 
cerebrovascular disease (CVD) (as specified by NINDS/
AIREN criteria) or probable VaD (NINDS/AIREN) were 
admitted32 if they scored 35 or worse in the cognitive part of 
the Test for Early Detection of Dementia with Discrimina-
tion from Depression (TE4D-cog),33 between 9 and 23 in 
the SKT cognitive test battery total score,34,35 below 6 in the 
clock-drawing test (CDT),36 and at least 5 on the 12-item 
Neuropsychiatric Inventory (NPI).7 In at least one item of the 
NPI (except delusions or hallucinations), patients had to score 
at least 3, and their total score on the Hamilton Rating Scale 
for Depression (HAMD) had to be less than 20.37 A caregiver 
had to be available to provide information on the patient’s 
behavior and ability to perform activities of daily living.
Patients suffering from other psychiatric or neurological 
disorders or having severe somatic illnesses were excluded. 
Treatment with other antidementia drugs, Ginkgo supple-
ments, cholinergic, anti-cholinergic or hemorheologically 
active drugs was prohibited throughout the trial.
study design and intervention
After a medication-free screening period of up to 4 weeks, 
patients were randomly assigned to receive either Ginkgo 
biloba extract EGb 761® at a dose of 240 mg once a day 
or placebo in a double-blind fashion during the subsequent 
24-week treatment period. EGb 761® is a dry extract from 
Ginkgo biloba leaves (35–67:1), extraction solvent: acetone 
60% (w/w). The extract is adjusted to 22.0%–27.0% Ginkgo 
flavonoids, calculated as Ginkgo flavone glycosides, and 
5.0%–7.0% terpene lactones, consisting of 2.8%–3.4% 
ginkgolides A, B, C, and 2.6%–3.2% bilobalide, and contains 
less than 5 ppm ginkgolic acids. Drug and placebo were Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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manufactured and provided by Dr Willmar Schwabe GmbH 
and Co. KG, Karlsruhe, Germany.
Outcome measures
Considering the emphasis on neuropsychiatric features 
at inclusion, the 12-item NPI was chosen to be a primary 
efficacy measure in addition to the SKT (a cross-culturally 
validated 9-item cognitive test battery). Each of the 12 types 
of abnormal behavior is explored by a number of pertinent 
screening questions and, if present, scored by its frequency 
of occurrence and its severity. The total composite score 
obtained by summing up the single item scores may range 
from 0 to 144, with higher scores indicating more behavioral 
problems.
In addition, a score for caregivers’ distress is assigned for 
each type of abnormal behavior present. The total distress 
score may range from 0 to 60, with higher scores indicating 
more severe distress suffered by the caregiver. An improve-
ment in the total composite score by four points or more in 
an individual patient is judged by experts to be clinically 
significant.38
The NPI caregivers’ distress score and the rate of clini-
cally meaningful response (improvement by at least 4 points 
on the NPI composite score) were therefore also included as 
secondary outcome measures.
Efficacy assessments were performed at baseline, 
week 12, and week 24. Safety was assessed by physical 
examination, electrocardiography, and laboratory tests at 
screening and week 24. Adverse events were recorded at all 
regular visits, at week 6, and week 18 by phone calls and at 
the study termination visit (week 24 or early termination).
statistical analysis
The methods for the statistical analysis are described in 
detail elsewhere.12 In short, two primary endpoints, the 
change in the SKT total score and the NPI total score, were 
defined to assess efficacy in the cognitive and neuropsychi-
atric domain, respectively. These endpoints were analyzed 
using an overall type-I error rate of α = 0.05 by applying 
an analysis of covariance procedure with the factors treat-
ment and center and the baseline value of the respective 
variable as a covariate. The analysis was based on the full 
analysis dataset according to the intention-to-treat principle 
and included all patients who received randomized study 
treatment at least once and had at least one measurement 
of the primary efficacy parameters during the randomized 
treatment period. Secondary efficacy variables as presented 
in this paper were evaluated   descriptively without control of 
the type-I error rate, and the P-values should be considered 
accordingly.
Results
The main results for the primary and secondary outcome 
parameters of this randomized, placebo-controlled clinical 
trial have been reported elsewhere.12 Here we describe the 
treatment effects of EGb 761® and placebo on neuropsychi-
atric symptoms of dementia derived from single NPI items, 
total composite scores, and caregiver distress scores.
Baseline characteristics of patients, broken down by treat-
ment group, are presented in Table 1. The mean NPI total 
score dropped by −3.2 ± 6.1 (mean ± standard deviation) 
points in the EGb 761®-treated patients between baseline 
and week 24. The mean caregiver distress score decreased in 
parallel by −1.2 ± 3.4 points. In patients receiving placebo, 
the NPI total score remained unchanged (0.0 ± 6.1), and the 
corresponding caregiver distress score increased slightly by 
0.3 ± 3.4. Drug–placebo differences were statistically sig-
nificant (P , 0.001, two-sided t-test) in both between-group 
comparisons. A clinically meaningful response, defined as an 
improvement by at least 4 points on the NPI total score,38 was 
achieved in 45.0% of patients treated with EGb 761® and in 
23.8% of patients receiving placebo (P , 0.001, two-sided 
χ2-test, for between-group comparison).
The mean composite and distress scores at baseline for 
all 12 NPI items are shown in Table 2. The highest base-
line composite scores were found for apathy/indifference, 
sleep/night-time behavior, irritability/lability, and anxiety. 
Table 1 Baseline characteristics of patients (full analysis set), 
means ± standard deviations and two-sided P-values of the t-test 
or numbers (percentage) and two-sided P-values of the χ2-test, 
as appropriate
Characteristic EGb 761®  
(n = 202)
Placebo  
(n = 202)
P-value
gender
  Female 139 (69%) 133 (66%) 0.524
  Male 63 (31%) 69 (34%)
Diagnosis
  probable AD 64 (32%) 57 (28%) 0.364
  possible AD with cVD 99 (49%) 113 (56%)
  probable VaD 39 (19%) 32 (16%)
Age (years) 65 ± 10 65 ± 9 0.550
height (cm) 166 ± 8 167 ± 8 0.298
Weight (kg) 74 ± 14 74 ± 14 0.666
sKT total score 16.7 ± 3.9 17.2 ± 3.7 0.163
NPi total score 16.4 ± 8.1 17.0 ± 8.2 0.393
NPi distress score 9.6 ± 5.6 10.0 ± 5.4 0.477
Abbreviations:  AD,  Alzheimer’s  disease;  cVD,  cerebrovascular  disease;  NPi, 
Neuropsychiatric inventory; sKT, erzigkeit’s short syndrome test; VaD, vascular 
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Table 2 Neuropsychiatric inventory item scores at baseline (full analysis set), means ± standard deviations and two-sided P-values of 
the t-test
Item Composite scorea Caregiver distress score
EGb 761® Placebo P-value EGb 761® Placebo P-value
Delusions 0.1 ± 0.5 0.0 ± 0.3 0.990 0.0 ± 0.3 0.1 ± 0.5 0.228
hallucinations 0.0 ± 0.2 0.0 ± 0.1 0.771 0.0 ± 0.3 0.1 ± 0.4 0.694
Agitation/aggression 0.7 ± 1.5 0.7 ± 1.4 0.856 0.6 ± 1.1 0.5 ± 1.1 0.922
Depression/dysphoria 2.6 ± 2.3 2.5 ± 2.4 0.998 1.5 ± 1.3 1.5 ± 1.3 0.817
Anxiety 3.4 ± 2.3 3.2 ± 2.4 0.422 1.9 ± 1.2 1.8 ± 1.2 0.322
elation/euphoria 0.3 ± 0.9 0.3 ± 1.0 0.443 0.2 ± 0.6 0.2 ± 0.7 0.490
Apathy/indifference 3.0 ± 2.4 2.9 ± 2.6 0.695 1.7 ± 1.2 1.6 ± 1.3 0.482
Disinhibition 0.3 ± 1.1 0.4 ± 1.2 0.370 0.3 ± 0.9 0.4 ± 1.0 0.329
irritability/lability 2.8 ± 2.3 3.1 ± 2.3 0.235 1.8 ± 1.3 1.9 ± 1.3 0.445
Aberrant motor behavior 0.6 ± 1.4 0.5 ± 1.4 0.805 0.5 ± 1.0 0.4 ± 0.9 0.506
sleep and night-time behavior 2.7 ± 2.3 2.4 ± 2.2 0.250 1.3 ± 1.1 1.3 ± 1.1 0.393
Appetite and eating disorders 0.5 ± 1.5 0.6 ± 1.6 0.385 0.2 ± 0.8 0.3 ± 0.7 0.759
Note: afrequency × severity.
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Figure 1 Changes from baseline to week 24 in composite scores of the Neuropsychiatric Inventory by item (means, 95% confidence intervals).
Notes: +P , 0.1; *P , 0.05.
Caregivers reported that irritability/lability, sleep/night-time 
behavior, and apathy/indifference were the most distressing 
symptoms.
As shown in Figure 1, the average improvements in NPI 
composite scores after the 24-week EGb 761® treatment period 
were most pronounced for sleep/night-time behavior, apathy/
indifference, irritability/lability, aberrant motor behavior, and 
depression/dysphoria (all statistically significantly different 
from placebo as indicated in   Figure 1). A similar effect pro-
file is observed for changes in caregiver distress scores, with 
marked effects also observed in sleep/night-time behavior and 
depression/dysphoria (statistically significantly different from 
placebo as indicated in Figure 2).
EGb 761® was safe and well tolerated, with a lower num-
ber of adverse events reported in the active treatment group 
than in the placebo group. Specifically, dizziness and tinnitus 
occurred more frequently under placebo treatment. Details 
have been reported and discussed elsewhere.12
Discussion
Significant treatment effects of a once-daily application of 
240 mg EGb 761® on many of the neuropsychiatric   symptoms Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Figure 2 Changes from baseline to week 24 in caregiver distress scores of the Neuropsychiatric Inventory by item (means, 95% confidence intervals). 
Notes: +P , 0.1; *P , 0.05.
evaluated by the 12-item NPI were found in prospective 
secondary analyses of this clinical trial. These results further 
support the efficacy of the once-daily application of Ginkgo 
biloba extract EGb 761® in the treatment of patients with 
AD, VaD, or dementia with mixed pathology associated with 
NPSs, as demonstrated by confirmatory primary analysis 
based on the NPI total score.
Clinical efficacy of EGb 761® in the treatment of NPSs 
has already been postulated by Hoerr, who reviewed former 
studies in patients with age-associated cognitive decline, 
and it was confirmed recently by Scripnikov for patients 
with dementia.13,15 Our clinical trial focused on patients 
with dementia – AD, VaD, or mixed type – who were 
selected specifically as suffering from NPSs. This was 
achieved by stipulating a baseline composite score of at 
least 5 points on the 12-item NPI, with at least one item 
score not lower than 3. The NPI total composite score also 
served as a co-primary outcome criterion for the efficacy 
assessment.
The profile of NPSs in our population is slightly   different 
from those reported in a previous 22-week trial of EGb 761®, 
and the baseline severity of symptoms is lower.15,39 Disease 
severity and stage-specific differences in behavioral symptom 
manifestations might influence overall treatment response as 
measured by an aggregate assessment tool such as NPI.40 As 
a consequence, the reported response rate (improvement by 
at least 4 points) might be lower in our clinical trial, in which 
the deterioration of symptoms in the placebo group was less 
pronounced, and even some slight improvement was observed 
in some symptoms with placebo treatment.
The pattern of neuropsychiatric symptoms found in our 
patients was consistent with that reported from a population-
based study in which patients with dementia also scored 
highest for the symptoms apathy/indifference, anxiety, 
depression/dysphoria, agitation/aggression, aberrant motor 
behavior, and irritability/lability.3 It therefore appears that 
our sample was quite representative of dementia patients 
encountered in everyday practice.
The caregiver distress scores at baseline closely match 
those of the NPI composite scores, with slight differences in 
ranking of severity of apathy/indifference, sleep/night-time 
behavior, and irritability/lability. Overall, the symptoms 
rated as most prominent in the patients were also perceived 
as most disturbing by the caregivers. Similarly, the relief 
from distress, which was experienced by caregivers during 
the treatment period, seems to be driven by the symptoms 
that improved most in the patients.
The elevation and stabilization of mood and the observed 
decrease in anxiety levels seem to be in line with the effects 
of EGb 761® on the dopamine and serotonin systems as well 
as on the HPA axis.24–29
Recently, a pooled data analysis of the moderate-affinity 
N-methyl-D-aspartate receptor antagonist memantine, 
a descriptive review of cholinesterase inhibitors and meman-
tine, and a review of randomized, placebo-controlled trials 
of donepezil, rivastigmine, and galantamine summarized the Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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evidence for the efficacy of these substances in the   treatment 
of NPSs.40–42 Beneficial effects of memantine were reported 
for delusions and agitation/aggression in patients with 
moderate to severe AD.41 Cummings concluded that most 
double-blind, placebo-controlled trials and open-label assess-
ments suggest some treatment benefit of antidementia agents, 
though not all demonstrated drug–placebo   differences.40 
This is consistent with the summary conclusion that, at best, 
cholinesterase inhibitors appear to have a modest impact on 
the broad spectrum of NPSs in AD. In contrast, EGb 761® 
showed a significant effect on a broad range of symptoms. 
However, caution is warranted when trying to compare treat-
ment effects observed in different studies, because they may 
depend on the characteristics of the particular patient popu-
lation, such as profile and severity of behavioral symptoms 
at baseline, severity or stage of dementia, residential status, 
linguistic and cultural diversities of study sites, and use of 
psychotropic drugs. Moreover, the 10-item version of the 
NPI was used in some of the earlier trials.
In summary, the present, and a previous independent trial 
in patients selected using the same criteria for dementia and 
NPSs,15 consistently demonstrated statistically significant 
and clinically relevant drug–placebo differences in favor 
of EGb 761® for the composite score, the caregiver distress 
score, and several NPI item scores (eg, apathy/indifference, 
sleep/night-time behavior, irritability/lability, depression/
dysphoria). The importance of alleviating NPSs is underlined 
by the negative impact such symptoms have on the quality of 
life of patients with dementia,43–45 the burden experienced by 
caregivers, and the roles that NPSs and NPS-related caregiver 
distress play in decisions about nursing home placement.46–48
Conclusion
It can be concluded that Ginkgo biloba extract EGb 761® at 
a once-daily dose of 240 mg is safe and effectively alleviates 
NPSs in patients with AD, VaD, and dementia with mixed 
pathology, benefitting both patients and their caregivers.
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